 It was initially used in the treatment of rheumatoid arthritis, but it is now also used in patients with moderate-to-severe Crohn's disease and ulcerative colitis who don't respond well to conventional treatment.Adalimumab showed effectiveness in patients with Crohn's disease, but less than that of infliximab.It was the best selling drug in 2017 with sales upwards of $18 billion.